We appreciate the interest and the comments by Ziegelstein regarding our article.1 Ziegelstein pointed out that the lack of long-term clopidogrel use among patients with NSTE ACS may be related to the fact that the guideline recommendation regarding use of clopidogrel after discharge is currently based on the results of only 1 clinical trial, the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial.2 Moreover, Ziegelstein found the results of the CURE trial itself not convincing, because the benefit of clopidogrel was partially counterbalanced by an increased bleeding risk.
Tricoci P, Roe MT, Peterson ED. Clopidogrel in Patients With Acute Coronary Syndromes: Learning From Clinical Practice—Reply. Arch Intern Med. 2006;166(20):2293. doi:10.1001/archinte.166.20.2293
Best of JAMA Network 2022
Customize your JAMA Network experience by selecting one or more topics from the list below.